CLC bio Part of $ 10M EU PATHSEEK Project
CLC bio, the world's leading bioinformatics software developer, has been awarded a share of a EU-funded clinical research grant, PATHSEEK, worth $ 2 million out of a total project budget of $ 10 million.
As part of the grant, CLC bio will develop a user-friendly and computationally efficient solution for pathogen identification, host biomarker identification, pathogen variant characterization and molecular epidemiology in a clinical setting, as well as build a flexible computational back-end.
VP of R&D at CLC bio, Dr. Roald Forsberg, comments, ""
CEO of CLC bio, Thomas Knudsen, adds, ""
PATHSEEK is a 3-year study led by Professor Judy Breuer at University College London, which will demonstrate the potential of next generation sequencing technologies in clinical microbiology labs, to enable the detection of pathogens directly from clinical samples and the early detection of drug resistant mutations. The study will look at infections with clear unmet clinical needs or which pose a global risk, including, HIV, , hepatitis B (HBV) and C (HCV) and influenza A. PATHSEEK will also investigate two host pharmacogenomics biomarkers which predict response to therapy for HCV and HIV.
The partners in PATHSEEK include University College London (UK), Erasmus Universitair Medisch Centrum Rotterdam (NL), Oxford Gene Technology (UK), and CLC bio (DK).